bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2018-2-70-79bekhterev-197Research ArticleНАУЧНО-ИССЛЕДОВАТЕЛЬСКИЕ РАБОТЫRESEARCH PAPERSУпотребление прегабалина ВИЧ-инфицированными больными с синдромом зависимости от опиоидовPregabalin use in HIV-infected patients with opioid dependence syndromeКиссинМихаил ЯковлевичKissinM. Ya.kissin.m@yandex.ruХалезоваНадежда БорисовнаKhalezovaN. B.khalezo@gmail.comГибитоваЕкатерина АркадьевнаGibitovaE. A.e.gibitova@yandex.ruТарноруцкаяАрина ВитальевнаTarnorutskayaA. V.tarnoruckaia@gmail.comИвановАлександр НиколаевичIvanovA. N.sart79@list.ruГБОУП ВПО МЗ РФ «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова»РоссияFirst St. Petersburg State Medical University named akad. I.P.Pavlov, Saint-PetersburgRussian FederationГБОУП ВПО МЗ РФ «Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова»; СПбГБУЗ «Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»РоссияFirst St. Petersburg State Medical University named akad. I.P.Pavlov, Saint-Petersburg; Center for Prevention and Control of HIV and infectious diseases, Saint-PetersburgRussian FederationСПбГБУЗ «Центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»РоссияCenter for Prevention and Control of HIV and infectious diseases, Saint-PetersburgRussian Federation201809112018027079Copyright © Киссин М.Я., Халезова Н.Б., Гибитова Е.А., Тарноруцкая А.В., Иванов А.Н., 20182018Киссин М.Я., Халезова Н.Б., Гибитова Е.А., Тарноруцкая А.В., Иванов А.Н.Kissin M.Y., Khalezova N.B., Gibitova E.A., Tarnorutskaya A.V., Ivanov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/197

Целью исследования являлось изучение аддиктивного потенциала прегабалина у длительно принимающих его ВИЧ-инфицированных больных с синдромом зависимости от опиоидов. Проводилось кросс-секционное исследование в Санкт-Петербургском Центре по профилактике и борьбе с ВИЧ и инфекционными заболеваниями. Обследована когорта из 572 ВИЧ-инфицированных больных с синдромом зависимости от опиоидов. 96 больных (16,8% среди всей когорты) употребляли прегабалин. 34 пациента из 96 согласились на участие в исследовании. У 23 из 34 обследованных ВИЧинфицированных больных с синдромом зависимости от опиоидов диагностирован также синдром зависимости от прегабалина. Группой риска зависимости от прегабалина являются люди с опиоидной зависимостью и наличием психоорганического синдрома различного генеза (токсического, посттравматического, инфекционного). У 11 из 34 больных было зарегистрировано применение прегабалина с терапевтической целью в схемах самолечения синдрома отмены опиоидов.

Te purpose of the current study was to identify an abuse potential of pregabalin in HIVinfected patients with opioid use disorder long time using pregabaline. A cross-sectional study was performed at the St. Petersburg Center for the prevention and control of HIV and infectious diseases. A cohort of 572 HIV-infected patients with opioid use disorder was examined. 96 patients (16,8% of the entire cohort) used pregabalin. 34 of them agreed to participate in the study. Te pregabalin addiction was diagnosed in 23 of 34 observed HIV-infected patients with opioid dependence. People with opioid dependence and presence of organic brain damage of various genesis (toxic exposure, neurological consequences of trauma or infection) are at risk of development of pregabalin dependence. Te use of pregabalin with for self-medication of opiod withdrawal was registered in 11 patients.

синдром зависимости от опиоидовпрегабалинВИЧ-инфекциясиндром отмены опиоидов.opioid dependencepregabalinHIV infectionopioid withdrawalReferencesАксючиц И.В. Методика изучения мотивов употребления наркотиков / И.В. Аксючиц // Психологический журнал. — 2007. — №1. — С.52-59.Aksyuchits I.V. Metodika izucheniya motivov upotrebleniya narkotikov / I.V. Aksyuchits // Psikhologicheskiy zhurnal. — 2007. — №1. — S.52-59.Киссин М.Я., Бондаренко И.И. Прегабалин и алпразолам в лечении генерализованного тревожного расстройства у больных с парциальной эпилепсией // Эпилепсия и пароксизмальные состояния. — 2010. — Т. 2. - № 2. — С.17-24.Kissin M.YA., Bondarenko I.I. Preparaty i protivorakovyye preparaty. — 2010. — T. 2. — № 2. — S. 17-24.Киссин М.Я., Бондаренко И.И. Применение прегабалина и сертралина в комплексной терапии больных парциальной эпилепсией с депрессивными и тревожными расстройствами // Журнал неврологии и психиатрии им. C.C. Корсакова. — 2012. — Т. 112. - № 5. — С. 29-36.Kissin M.YA., Bondarenko I.I. Primeneniye pregabalina i sertralina v kompleksnoy terapii bol’nykh partsial’noy epilepsiyey s depressivnymi i trevozhnymi rasstroystvami // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. — 2012. — T. 112. — № 5. — S. 29-36.Крупицкий Е.М., Илюк Р.Д., Михайлов А.Д., Казанков К.А., Рыбакова К.В., Скурат Е.П., Гришина О.Г., Заплаткин И.А., Ветрова М.В., Незнанов Н.Г. Рандомизированное контролируемое исследование эффективности прегабалина в терапии синдрома отмены опиатов // Журнал неврологии и психиатрии им. С.С.Корсакова. — 2016. — Т. 116. - № 7. — С. 29-36.Krupitskiy Ye.M., Ilyuk R.D., Mikhaylov A.D., Kazankov K.A., Rybakova K.V., Skurat Ye.P., Grishina O.G., Zaplatkin I.A., Vetrova M.V., Neznanov N.G. Randomizirovannoye kontroliruyemoye issledovaniye effektivnosti pregabalina v terapii sindromares opiatov // Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. — 2016. — T.116. — №7. — S.29-36.Крупицкий Е.М., Рыбакова К.В., Скурат Е.П., Михайлов А.Д, Незнанов Н.Г. Двойное слепое рандомизированное плацебо-контролируемое исследование эффективности применения прегабалина для лечения синдрома зависимости от алкоголя // Вопросы наркологии. — 2015. — С.81-82.Krupitskiy Ye.M., Rybakova K.V., Skurat Ye.P., Mikhaylov A.D, Neznanov N.G. Dvoynoye slepoye randomizirovannoye platsebo-kontroliruyemoye issledovaniye effektivnosti primeneniya pregabalina dlya lecheniya sindroma zavisimosti ot alkogolya // Voprosy narkologii. — 2015. — S.81-82.Рохлина М.Л., Ненастьева А.Ю., Усманова Н.Н., Захаров Е.Д., Демурова В.Н. Злоупотребление прегабалином (Лирикой). - Вопросы наркологии. – 2015. — №3. — С.9-15.Rokhlina M.L., Nenast’yeva A.YU., Usmanova N.N., Zakharov Ye.D., Demurova V.N. Zloupotrebleniye pregabalinom (Lirikoy). — Voprosy narkologii. — 2015. — T.3. — S.9-15.Baird C.R., Fox P., Colvin L.A. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. — Eur Addict Res. — 2014. — Vol.20. — P.115-118.Baird C.R., Fox P., Colvin L.A. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. — Eur Addict Res. — 2014. — Vol.20. — P.115-118.Berg M.L., Idrees U., Ding R., et al. Evaluation of the use of buprenor-phine for opioid withdrawal in an emergency department. — Drug Alcohol Depend. — 2007. — Vol.86. — P.239–244.Berg M.L., Idrees U., Ding R., et al. Evaluation of the use of buprenor-phine for opioid withdrawal in an emergency department. — Drug Alcohol Depend. — 2007. — Vol.86. — P.239–244.Bobes J., Rubio G., Teran A., et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. — Eur Psychiatry. — 2011. Published online 18 February 2011.Bobes J., Rubio G., Teran A., et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. — Eur Psychiatry. — 2011. Published online 18 February 2011.Boschen M.J. A meta-analysis of the efcacy of pregabalin in the treatment of generalized anxiety disorder. — Can J Psychiatry. — 2011. — Vol.56. — P.558-566.Boschen M.J. A meta-analysis of the efcacy of pregabalin in the treatment of generalized anxiety disorder. — Can J Psychiatry. — 2011. — Vol.56. — P.558-566.Cabrera J., Emir B., Dills D., et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. — Curr Med Res Opin. — 2012. Published online 12 April 2012.Cabrera J., Emir B., Dills D., et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. — Curr Med Res Opin. — 2012. Published online 12 April 2012.Carnwath T., Hardman. J. Randomized doubleblind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal. — Drug Alcohol Depend. — 1998. — P.251–254.Carnwath T., Hardman. J. Randomized doubleblind comparison of lofexidine and clonidine in the outpatient treatment of opiate withdrawal. — Drug Alcohol Depend. — 1998. — P.251–254.Carrus D., Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. — J. Clin Psychopharmacol. — 2012. — Vol.32. — P.839-840.Carrus D., Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. — J. Clin Psychopharmacol. — 2012. — Vol.32. — P.839-840.Dart R., Woody. G., Kleber H. Prescribing methadone as an analgesic. - Ann Intern Med. – 2005. — P.143-620.Dart R., Woody. G., Kleber H. Prescribing methadone as an analgesic. - Ann Intern Med. – 2005. — P.143-620.Di Nicola M., Martinotti G., Tedeschi D., et al. Pregabalin in outpatient detoxifcation of subjects with mild-to-moderate alcohol withdrawal syndrome. — Hum Psychopharmacol. — 2010. — Vol.25. — P.268–275.Di Nicola M., Martinotti G., Tedeschi D., et al. Pregabalin in outpatient detoxifcation of subjects with mild-to-moderate alcohol withdrawal syndrome. — Hum Psychopharmacol. — 2010. — Vol.25. — P.268–275.Di Nicola M., Tedeschi D., Martinotti G., et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. — J Clin Psychopharmacol. — 2011. — Vol.31. — P.675-677.Di Nicola M., Tedeschi D., Martinotti G., et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. — J Clin Psychopharmacol. — 2011. — Vol.31. — P.675-677.Dyer C. Addict died afer rapid opiate detoxifcation. — BMJ. — 1998. — P.316-370.Dyer C. Addict died afer rapid opiate detoxifcation. — BMJ. — 1998. — P.316-370.Einarsdottir S., Bjornsson E.. Pregabalin as a probable cause of acute liver injury. — Eur J Gastroenterol Hepatol. — 2008. — Vol.20. — P.1049.Einarsdottir S., Bjornsson E.. Pregabalin as a probable cause of acute liver injury. — Eur J Gastroenterol Hepatol. — 2008. — Vol.20. — P.1049.Feltner D.E., Liu-Dumaw M., Schweizer E., et al. Efcacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fxed-dose study. — Int Clin Psychopharmacol. — 2011. — Vol.26. — P.213-220.Feltner D.E., Liu-Dumaw M., Schweizer E., et al. Efcacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fxed-dose study. — Int Clin Psychopharmacol. — 2011. — Vol.26. — P.213-220.Filipetto F.A., Zipp C.P., Coren J.S. Potential for pregabalin abuse or diversion afer past drug-seeking behavior. — Te Journal of the American Osteopathic Association. — 2010. — Vol.110. — P.605-607.Filipetto F.A., Zipp C.P., Coren J.S. Potential for pregabalin abuse or diversion afer past drug-seeking behavior. — Te Journal of the American Osteopathic Association. — 2010. — Vol.110. — P.605-607.Folstein MF, Folstein SE, Hugh PR Mini-mental state examination: a practical method for grading the cognitive state of patients for the clinician. — Psychatric Research. — 1975. –Vol.12. — P.189.Folstein MF, Folstein SE, Hugh PR Mini-mental state examination: a practical method for grading the cognitive state of patients for the clinician. — Psychatric Research. — 1975. –Vol.12. — P.189.Forg A., Hein J., Volkmar K., et al. Efcacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol.—2012.—Vol.47.—P.149-155.Forg A., Hein J., Volkmar K., et al. Efcacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol.—2012.—Vol.47.—P.149-155.Gahr M., Freudenmann R.W., Hiemke C., Kölle M.A., Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. -Eur J Clin Pharmacol. — 2013. — Vol.69. — P.1335-1342.Gahr M., Freudenmann R.W., Hiemke C., Kölle M.A., Schönfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. -Eur J Clin Pharmacol. — 2013. — Vol.69. — P.1335-1342.Gold C.G., CuIIen D.J., Gonzales S., et al. Rapid opioid detoxifcation during general anesthesia: a review of 20 patients. — Anesthesiology. — 1999. — Vol.91. — P.1639–1647.Gold C.G., CuIIen D.J., Gonzales S., et al. Rapid opioid detoxifcation during general anesthesia: a review of 20 patients. — Anesthesiology. — 1999. — Vol.91. — P.1639–1647.Gossop M., Johns A., Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. — BMJ (Clin Res Ed). — 1986. — Vol.293. — P.103–104.Gossop M., Johns A., Green L. Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. — BMJ (Clin Res Ed). — 1986. — Vol.293. — P.103–104.Gowing L., Ali, R., White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. — 2003. — Vol.69. — P.283–288.Gowing L., Ali, R., White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. — 2003. — Vol.69. — P.283–288.Grosshans M., Lemenager T., Vollmert C., Kaemmerer N., Schreiner R., Mutschler J., Wagner X., Kiefer F., Hermann D. Pregabalin abuse among opiate addicted patients. — Eur J Clin Pharmacol. — 2013. — Vol.69. — P.2021-2025.Grosshans M., Lemenager T., Vollmert C., Kaemmerer N., Schreiner R., Mutschler J., Wagner X., Kiefer F., Hermann D. Pregabalin abuse among opiate addicted patients. — Eur J Clin Pharmacol. — 2013. — Vol.69. — P.2021-2025.Grosshans M., Mutschler J., Hermann D., Klein O., Dressing H., Kiefer F., Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. — Am J Psychiatry. — 2010. — Vol.167. — P.869.Grosshans M., Mutschler J., Hermann D., Klein O., Dressing H., Kiefer F., Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. — Am J Psychiatry. — 2010. — Vol.167. — P.869.Hamilton R.J., Olmedo R.E., Shah S., et al. Complications of ultra-rapid opioid detoxifcation with subcutaneous naltrexone pellets. — Acad Emerg Med. — 2002. — Vol.63 — P.68.Hamilton R.J., Olmedo R.E., Shah S., et al. Complications of ultra-rapid opioid detoxifcation with subcutaneous naltrexone pellets. — Acad Emerg Med. — 2002. — Vol.63 — P.68.Harmark L., van Puijenbroek E., Straus S., et al. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. — Drug Saf. — 2011. — Vol.34. — P.221-231.Harmark L., van Puijenbroek E., Straus S., et al. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. — Drug Saf. — 2011. — Vol.34. — P.221-231.Hindmarch I., Dawson J., Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. — Sleep. — 2005. — Vol.28. — P.187-193.Hindmarch I., Dawson J., Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. — Sleep. — 2005. — Vol.28. — P.187-193.Kahn A., Mumford J.P., Rogers. G.A., et al. Double blind study of lofexidine and clonidine in the detoxifcation of oopiate addicts in hospital. — Drug Alcohol Depend. — 1997. — P.57–61.Kahn A., Mumford J.P., Rogers. G.A., et al. Double blind study of lofexidine and clonidine in the detoxifcation of oopiate addicts in hospital. — Drug Alcohol Depend. — 1997. — P.57–61.Lintzeris N., Bell J., Bammer G., et al. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. — Addiction. — 2002. — P.1395–1404.Lintzeris N., Bell J., Bammer G., et al. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. — Addiction. — 2002. — P.1395–1404.Martinotti G., di Nicola M., Frustaci A., et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. — Addiction. — 2010. — Vol.105. — P.288-299.Martinotti G., di Nicola M., Frustaci A., et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. — Addiction. — 2010. — Vol.105. — P.288-299.Martinotti G., Di Nicola M., Tedeschi D., et al. Efcacy and safety of pregabalin in alcohol dependence. — Adv Ter. — 2008. — Vol.25. — P.608-618.Martinotti G., Di Nicola M., Tedeschi D., et al. Efcacy and safety of pregabalin in alcohol dependence. — Adv Ter. — 2008. — Vol.25. — P.608-618.Martinotti G., Di Nicola M., Tedeschi D., et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. — J Psychopharmacol. — 2010. — Vol.24. — P.1367-1374.Martinotti G., Di Nicola M., Tedeschi D., et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. — J Psychopharmacol. — 2010. — Vol.24. — P.1367-1374.Nordgaard J., Jürgens G. Pregabalin can cause addiction and withdrawal symptoms. Ugeskr Laeger. — 2015. — Vol.26. — P.38-39.Nordgaard J., Jürgens G. Pregabalin can cause addiction and withdrawal symptoms. Ugeskr Laeger. — 2015. — Vol.26. — P.38-39.O’Connor P.G., Kosten T.R. Rapid and ultrarapid opioid detoxifcation techniques. — JAMA. — 1998. — Vol.279. — P.229–234.O’Connor P.G., Kosten T.R. Rapid and ultrarapid opioid detoxifcation techniques. — JAMA. — 1998. — Vol.279. — P.229–234.Oulis P., Florakis A.A., Tzanoulinos G., et al. Adjunctive pregabalin to quetiapine in acute mania. — Clin Neuropharmacol. — 2009. — Vol.32. — P.174.Oulis P., Florakis A.A., Tzanoulinos G., et al. Adjunctive pregabalin to quetiapine in acute mania. — Clin Neuropharmacol. — 2009. — Vol.32. — P.174.Oulis P., Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. — CNS Neurosci Ter. — 2010. — Vol.16. — P.45-50.Oulis P., Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. — CNS Neurosci Ter. — 2010. — Vol.16. — P.45-50.Oulis P., Konstantakopoulos G., Kouzoupis A.V., et al. Pregabalin in the discontinuation of longterm benzodiazepines’ use. — Hum Psychopharmacol. — 2008. — Vol.23. — P.337-340.Oulis P., Konstantakopoulos G., Kouzoupis A.V., et al. Pregabalin in the discontinuation of longterm benzodiazepines’ use. — Hum Psychopharmacol. — 2008. — Vol.23. — P.337-340.Pae C.U. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuropsychopharmacol. — Biol Psychiatry. — 2009. — Vol.33. — P.577-578.Pae C.U. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuropsychopharmacol. — Biol Psychiatry. — 2009. — Vol.33. — P.577-578.Papazisis G., Garyfallos G., Sardeli C., Kouvelas D. Pregabalin abuse afer past substanceseeking behavior. — Int J Clin Pharmacol Ter. — 2013. — Vol.51. — P.441-442.Papazisis G., Garyfallos G., Sardeli C., Kouvelas D. Pregabalin abuse afer past substanceseeking behavior. — Int J Clin Pharmacol Ter. — 2013. — Vol.51. — P.441-442.Pexton T., Moeller-Bertram T., Schilling J.M., et al. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. — Expert Opin Investig Drugs. — 2011. — Vol.20. — P.1277-1284.Pexton T., Moeller-Bertram T., Schilling J.M., et al. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. — Expert Opin Investig Drugs. — 2011. — Vol.20. — P.1277-1284.Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? — CNS Drugs. — 2014. — Vol.28. — P.491-496.Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? — CNS Drugs. — 2014. — Vol.28. — P.491-496.Schifano F., D’Ofzi S., Piccione M., et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. — Psychother Psychosom. — 2011. — Vol.80. — P.118-122.Schifano F., D’Ofzi S., Piccione M., et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. — Psychother Psychosom. — 2011. — Vol.80. — P.118-122.Schifano F., Leoni M., Martinotti G., et al. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. — Cyberpsychol Behav. — 2003. — Vol.6. — P.405-410.Schifano F., Leoni M., Martinotti G., et al. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. — Cyberpsychol Behav. — 2003. — Vol.6. — P.405-410.Schwan S., Sundström A., Stjernberg E., Hallberg E., Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. — Eur J Clin Pharmacol. — 2010. — Vol.66. — P.947-953.Schwan S., Sundström A., Stjernberg E., Hallberg E., Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. — Eur J Clin Pharmacol. — 2010. — Vol.66. — P.947-953.Strang J., Gossop M. Comparison of linear versus inverse exponential methadone reduction curves in the detoxifcation of opiate addicts. — Addict Behav. — 1990. — Vol.15. — P.541–547.Strang J., Gossop M. Comparison of linear versus inverse exponential methadone reduction curves in the detoxifcation of opiate addicts. — Addict Behav. — 1990. — Vol.15. — P.541–547.Taylor C.P., Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. — Epilepsy Res. — 2007. — Vol.73. — P.137-150.Taylor C.P., Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. — Epilepsy Res. — 2007. — Vol.73. — P.137-150.Whittington R.A., Collins E.D., Kleber H.D. Rapid opioid detoxifcation during general anesthesia: is death not a signifcant outcome? — Anesthesiology. — 2000. — Vol.93. — P.1363–1364.Whittington R.A., Collins E.D., Kleber H.D. Rapid opioid detoxifcation during general anesthesia: is death not a signifcant outcome? — Anesthesiology. — 2000. — Vol.93. — P.1363–1364.

The authors declare that there are no conflicts of interest present.